Prevention of ornithine cytotoxicity by nonpolar side chain amino acids in retinal pigment epithelial cells

Invest Ophthalmol Vis Sci. 2003 Nov;44(11):5023-8. doi: 10.1167/iovs.03-0403.

Abstract

Purpose: To investigate the effect of amino acids on ornithine cytotoxicity in ornithine-delta-aminotransferase (OAT)-deficient human retinal pigment epithelial (RPE) cells as an in vitro model of gyrate atrophy (GA) of the choroid and retina.

Methods: RPE cells were treated with 0.5 mM 5-fluoromethylornithine (5-FMOrn), a specific and irreversible OAT inhibitor. OAT-deficient RPE cells were incubated with 10 mM ornithine in the presence of 20 mM of 1 of 18 amino acids or 10 mM 2-amino-2-norbornane-carboxylic acid (BCH), a conventional inhibitor of the amino acid transporter system L. Ornithine cytotoxicity and cytoprotective effects of each amino acid was evaluated with a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) colorimetric assay 72 hours after treatment with ornithine in OAT-deficient RPE cells. Ornithine incorporation into RPE cells was evaluated using DL-[14C]ornithine.

Results: An MTT colorimetric assay revealed that small and large zwitterionic amino acids, but not acidic or basic amino acids, decreased ornithine cytotoxicity in OAT-deficient RPE cells. Incorporation of DL-[14C]ornithine by RPE cells decreased to 79% of the control level after incubation for 48 hours with 20 mM leucine, the most effective cytoprotective amino acid. Further, BCH prevented ornithine cytotoxicity in a dose-dependent manner. Both light and heavy chains of L-type amino acid transporter (LAT)-1, LAT2, y+LAT1, and 4F2hc were expressed in RPE cells.

Conclusions: The present results demonstrate that L-type amino acid transporter(s) may be involved in protection against ornithine cytotoxicity in human RPE cells. Thus, amino acid transportation in RPE cells may be a good target for a new therapy for GA as well as other kinds of chorioretinal degeneration.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acid Transport System y+*
  • Amino Acids / pharmacology*
  • Amino Acids, Cyclic / pharmacology
  • Cell Survival
  • Cells, Cultured
  • Colorimetry
  • Cytoprotection / drug effects*
  • Fusion Regulatory Protein 1, Heavy Chain / drug effects
  • Fusion Regulatory Protein 1, Heavy Chain / genetics
  • Fusion Regulatory Protein 1, Heavy Chain / metabolism
  • Fusion Regulatory Protein 1, Light Chains / drug effects
  • Fusion Regulatory Protein 1, Light Chains / genetics
  • Fusion Regulatory Protein 1, Light Chains / metabolism
  • Gyrate Atrophy / drug therapy
  • Gyrate Atrophy / metabolism
  • Humans
  • Large Neutral Amino Acid-Transporter 1 / drug effects
  • Large Neutral Amino Acid-Transporter 1 / genetics
  • Large Neutral Amino Acid-Transporter 1 / metabolism
  • Ornithine / analogs & derivatives*
  • Ornithine / toxicity*
  • Ornithine-Oxo-Acid Transaminase / antagonists & inhibitors
  • Ornithine-Oxo-Acid Transaminase / deficiency
  • Pigment Epithelium of Eye / drug effects*
  • Pigment Epithelium of Eye / metabolism
  • Pigment Epithelium of Eye / pathology
  • RNA, Messenger / metabolism
  • Reverse Transcriptase Polymerase Chain Reaction
  • Tetrazolium Salts
  • Thiazoles

Substances

  • Amino Acid Transport System y+
  • Amino Acids
  • Amino Acids, Cyclic
  • Fusion Regulatory Protein 1, Heavy Chain
  • Fusion Regulatory Protein 1, Light Chains
  • Large Neutral Amino Acid-Transporter 1
  • RNA, Messenger
  • SLC7A8 protein, human
  • Tetrazolium Salts
  • Thiazoles
  • 5-fluoromethylornithine
  • 2-aminobicyclo(2,2,1)heptane-2-carboxylic acid
  • Ornithine
  • Ornithine-Oxo-Acid Transaminase
  • thiazolyl blue